Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
ATI355
print preview
bookmark
share with colleague
General Information
Company
Novartis AG
Description
Monoclonal antibody (mAb) that inhibits NOGO
Molecular Target
Reticulon 4 (RTN4) (NOGO-A) (NOGO) (NOGO-B)
Mechanism of Action
Antibody
Latest Stage of Development
Phase I
Indication
Spinal cord injury (SCI)
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy